MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.6200
-0.0900 (-2.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.7100
Open3.6000
Bid3.46 x 4000
Ask3.78 x 4000
Day's Range3.5900 - 3.8300
52 Week Range3.3100 - 10.5400
Volume1,999,877
Avg. Volume1,260,158
Market Cap190.14M
Beta (3Y Monthly)5.27
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire4 days ago

    Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of $3.75 per share. The total public offering size is expected to be $45.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by the Company. The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,800,000 shares of common stock.

  • GlobeNewswire5 days ago

    Marinus Pharmaceuticals Announces Public Offering of Common Stock

    Marinus Pharmaceuticals, Inc. (MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering.  All of the shares in the offering are to be sold by Marinus.  Jefferies LLC and Leerink Partners LLC are acting as joint bookrunning managers for the offering. Marinus also expects to grant the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

  • GlobeNewswire7 days ago

    Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression

    Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced positive results from its Phase 2 clinical trials evaluating ganaxolone intravenous (IV) (the Magnolia Study) and oral (the Amaryllis Study) in women with postpartum depression (PPD). Based on these results, the Company is advancing both studies into the next phase of development to evaluate IV and oral dose regimens.

  • GlobeNewswire13 days ago

    Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that ganaxolone data from its Phase 2 clinical trial in pediatric genetic epilepsies, CDKL5 Deficiency Disorder (CDD) and PCDH19-related pediatric epilepsy (PCDH19 epilepsy) were presented at the American Epilepsy Society (AES) Annual Meeting in New Orleans on December 2 and 3, 2018.

  • GlobeNewswire28 days ago

    Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that two abstracts highlighting the results of clinical trials of ganaxolone in children with CDKL5 Deficiency Disorder (CDD) and PCDH19-related epilepsy have been selected for poster presentation at the American Epilepsy Society (AES) Annual Meeting in New Orleans on December 2 and 3, 2018.

  • GlobeNewswirelast month

    Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results

    RADNOR, Pa., Oct. 29, 2018 -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance

    Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice President of Clinical Development and Pharmacovigilance where he will primarily be responsible for the medical leadership of our postpartum depression (PPD) programs and drug safety. “Dr. Gutíerrez-Esteinou is a welcome addition to the management team at Marinus,” said Christopher Cashman, Chairman and CEO of Marinus Pharmaceuticals.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 120,000 shares of its common stock to a new employee, with a grant date of October 8, 2018. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates.  The stock options were granted as inducements material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 20,000 shares of its common stock each to two new employees, with grant dates of October 1 and October 3, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • GlobeNewswire3 months ago

    Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

    Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression. “The completion of enrollment in our Magnolia Study is an important milestone in studying PPD, for which there is currently no approved treatment,” said Christopher Cashman, chairman and CEO of Marinus Pharmaceuticals.

  • ACCESSWIRE3 months ago

    Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market

    HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies.

  • GlobeNewswire3 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 42,000 shares of its common stock to a new director and a new employee, with a grant date of September 19, 2018. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

  • ACCESSWIRE5 months ago

    Free Technical Research on Marinus Pharma and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.

  • ACCESSWIRE6 months ago

    Free Technical Reports on MannKind and Three Additional Biotech Equities

    This morning, WallStEquities.com is focused on the Biotech space, which is engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development. Under evaluation today are these four equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), and Neptune Technologies & Bioressources Inc. (NASDAQ: NEPT).